Data availability
Not applicable.
References
Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, Ruelle T, Pronzato P, Massarotti C, Franzoi MA, Lambertini M, Tagliamento M (2022) Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat 191(2):269–275
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
Sun P, Wang Y, Chen Z (2019) Meta-analysis should be done in a normative manner. Aesthet Plast Surg 43(4):1128–1129
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. The first draft of the manuscript was written by Weihong Nie and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nie, W., Ding, H. & Zou, X. Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis”. Breast Cancer Res Treat 193, 237–238 (2022). https://doi.org/10.1007/s10549-022-06542-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-022-06542-2